abstract |
The present invention generally relates to mutant interleukin-2 polypeptides which exhibit reduced affinity for the α-subunit of the IL-2 receptor for use as an immunotherapeutic agent. The invention also relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising said polynucleotide molecules. The invention also relates to methods of making mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising them, and uses thereof. |